801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOral Medications

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 0.5mg, 1.0mg

Payment & Shipping Terms:

Minimum Order Quantity: 500, 000 capsules
Price: Negotiation
Packaging Details: 10’s/blister
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: One million pills per day
Contact Now
Detailed Product Description
Product: Sirolimus Capsules Specification: 0.5mg, 1.0mg
Standard: In - House Packing: 10’s/blister

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

 

Product : Sirolimus Capsules

Specification : 0.5mg, 1.0mg

Standard : In - house

Packing : 10’s/blister

 

Description :

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

 

Indication

For the prophylaxis of organ rejection in patients receiving renal transplants.

 

Pharmacodynamics

Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.

 

Mechanism of action

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)